Carl H June

发表

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

Bernd Hauck, Bruce L Levine, David L Porter, 2013, The New England journal of medicine.

CRISPR-engineered T cells in patients with refractory cancer

Howard Y. Chang, Wei-Ting Hwang, Frederic D Bushman, 2020, Science.

Gene-based immunotherapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome.

Boro Dropulic, C. June, Carl H June, 2006, Human gene therapy.

Chimeric antigen receptor T cells for sustained remissions in leukemia.

Pamela A Shaw, Bruce L Levine, Yolanda D Mahnke, 2014, The New England journal of medicine.

Chimeric Antigen Receptor Therapy.

Michel Sadelain, M. Sadelain, C. June, 2018, The New England journal of medicine.

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.

Brian Keith, Ian A Blair, Avery D Posey, 2016, Immunity.

Human Genome Editing in the Clinic: New Challenges in Regulatory Benefit-Risk Assessment.

Toni Cathomen, Mohamed Abou-El-Enein, Zoltán Ivics, 2017, Cell stem cell.

PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR.

Bruce L Levine, B. Levine, C. June, 2017, Blood.

Genetic therapies against HIV

John J Rossi, Donald B Kohn, C. June, 2007, Nature Biotechnology.

Defining the critical hurdles in cancer immunotherapy

Zhigang Tian, Sylvia Janetzki, Cedrik M Britten, 2011, Journal of Translational Medicine.

Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling.

D. Teachey, J. Fish, G. Reid, 2011, Blood.

Antibody-modified T cells: CARs take the front seat for hematologic malignancies.

Marcela V Maus, David L Porter, S. Grupp, 2014, Blood.

Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases.

Rohan P Joshi, C. June, M. Riese, 2013, Cancer research.

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

Hans Bitter, Wei-Ting Hwang, Iulian Pruteanu-Malinici, 2018, Nature Medicine.

Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.

Brian Keith, Avery D Posey, Sonia Guedan, 2018, JCI insight.

Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells

Bent K Jakobsen, J. E. Brewer, Gabriela Plesa, 2013, Science Translational Medicine.

Adoptive T cell therapy for cancer in the clinic.

C. June, Carl H June, 2007, The Journal of clinical investigation.

Tat-functionalized near-infrared emissive polymersomes for dendritic cell labeling.

Guizhi Li, Daniel A Hammer, Frank S Bates, 2007, Bioconjugate chemistry.

Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load.

Richard Carroll, Bruce L Levine, Boro Dropulic, 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes.

Marcela V Maus, James L Riley, C. June, 2002, Clinical immunology.

Monoclonal TCR-redirected tumor cell killing

Yvonne McGrath, Yi Li, Bent K Jakobsen, 2012, Nature Medicine.

Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5.

Gabriela Plesa, Bruce L Levine, James L Riley, 2013, Human gene therapy.

Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells.

Frederic D Bushman, Bruce L Levine, Nirav Malani, 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

Is autoimmunity the Achilles' heel of cancer immunotherapy?

J. Bluestone, C. June, Carl H June, 2017, Nature Medicine.

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell

Hans Bitter, Tyler J. Reich, Frederic D Bushman, 2018, Nature Medicine.

Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV.

Wei-Ting Hwang, Ian Frank, Gabriela Plesa, 2014, The New England journal of medicine.

Principles of adoptive T cell cancer therapy.

C. June, Carl H June, 2007, The Journal of clinical investigation.

Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo

Raphael Sandaltzopoulos, D. Powell, C. June, 2013, Cancer Immunology Research.

T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma.

Wei-Ting Hwang, Bruce L Levine, B. Levine, 2019, Blood advances.

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

Adam Bagg, Marcela V Maus, Bent K Jakobsen, 2013, Blood.

Chimeric antigen receptor therapy for cancer.

David L Porter, S. Grupp, D. Porter, 2014, Annual review of medicine.

A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation.

Alexander Perl, Bruce L Levine, David L Porter, 2006, Blood.

Human T regulatory cell therapy: take a billion or so and call me in the morning.

James L Riley, C. June, B. Blazar, 2009, Immunity.

Driving cars to the clinic for solid tumors

Avery D Posey, C. June, M. Castellarin, 2018, Gene Therapy.